19-hydroxy-4-androstene-3-17-dione and Cushing-Syndrome

19-hydroxy-4-androstene-3-17-dione has been researched along with Cushing-Syndrome* in 3 studies

Other Studies

3 other study(ies) available for 19-hydroxy-4-androstene-3-17-dione and Cushing-Syndrome

ArticleYear
Elevated plasma 19-hydroxyandrostenedione levels in Cushing's disease: stimulation with ACTH and inhibition with metyrapone.
    Clinical endocrinology, 1993, Volume: 38, Issue:3

    The regulation of 19-hydroxyandrostenedione secretion has been suggested to be under the control of both the ACTH-adrenal axis and renin-angiotensin system. We undertook the present study to evaluate the effect of the chronic excess of ACTH, or the short-term excess of ACTH due to metyrapone, on 19-hydroxyandrostenedione secretion in patients with Cushing's disease.. We measured plasma 19-hydroxyandrostenedione levels simultaneously with plasma delta 4-androstenedione, corticosterone, 11-deoxycorticosterone, aldosterone and cortisol levels after HPLC separation in 13 patients with Cushing's disease under basal conditions and during a dexamethasone suppression test or metyrapone test. Seven patients with Cushing's syndrome due to adrenal adenoma were used for comparison.. The basal levels of 19-hydroxyandrostenedione in Cushing's disease were elevated (mean +/- SD; 323 +/- 193 pmol/l, n = 13), while those in Cushing's syndrome due to adrenal adenoma were low (92 +/- 24 pmol/l, n = 7), compared to those in normal subjects (117 +/- 33 pmol/l, n = 54). The basal levels of delta 4-androstenedione were mildly elevated in Cushing's disease (9.0 +/- 6.5 vs 3.6 +/- 2.6 nmol/l of normal subjects) but not in Cushing's syndrome due to adrenal adenoma (3.1 +/- 3.0 nmol/l). In the overnight 8 mg dexamethasone suppression test in Cushing's disease (n = 12), plasma levels of 19-hydroxyandrostenedione and delta 4-androstenedione decreased from 277 +/- 172 to 156 +/- 99 pmol/l and from 9.2 +/- 6.8 to 4.7 +/- 3.4 nmol/l, respectively, whereas the overnight 1 mg dexamethasone suppression test did not induce significant changes. Metyrapone administration in Cushing's disease (n = 9) increased plasma delta 4-androstenedione level from 9.5 +/- 6.7 to 47.2 +/- 28.1 nmol/l, but decreased plasma 19-hydroxyandrostenedione level from 301 +/- 196 to 196 +/- 105 pmol/l.. These data indicate that plasma levels of 19-hydroxyandrostenedione in patients with Cushing's disease are elevated due to chronic ACTH excess, and that metyrapone can inhibit 19-hydroxylation in humans.

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Androstenedione; Blood Pressure; Cushing Syndrome; Depression, Chemical; Dexamethasone; Female; Humans; Hydrocortisone; Male; Metyrapone; Middle Aged

1993
[Hypertensinogenic steroid].
    Nihon rinsho. Japanese journal of clinical medicine, 1989, Volume: 47, Issue:9

    Topics: 17-alpha-Hydroxyprogesterone; 18-Hydroxydesoxycorticosterone; Adrenal Hyperplasia, Congenital; Androstenedione; Blood Pressure; Cushing Syndrome; Humans; Hydroxyprogesterones; Hyperaldosteronism; Hypertension

1989
19-hydroxyandrostenedione, a new amplifier of the action of aldosterone, in low renin essential hypertension.
    Japanese journal of medicine, 1982, Volume: 21, Issue:2

    Topics: Addison Disease; Adrenocorticotropic Hormone; Aldosterone; Androstenedione; Cushing Syndrome; Female; Furosemide; Humans; Hypertension; Male

1982